Objective
Steroid resistant acute Graft versus Host Disease (GvHD) is a very serious complication
associated with allogeneic haematopoietic stem cell transplantation. There is no established consensus on the therapy for this disease and the prognosis for these patients is poor. Early reports of MSC therapy for acute GvHD involving small numbers of patients were promising, however, results from large scale multi-centre phase III trials have questioned the therapeutic efficacy of MSC therapy for GvHD. Our hypothesis is that MSC require licensing for therapeutic efficacy in GvHD. This project addresses a number of very important and clinically relevant questions; Why are IFN-gamma licensed MSC more efficacious in the treatment of acute GvHD in pre-clinical models? What are the differences between licensed and unlicensed MSC that facilitates the enhanced efficacy? The final element that this project will address is whether or not correlates of MSC therapeutic efficacy can be identified and translated into the clinic. This research is both internationally competitive and innovative in that no correlates have been identified for MSC therapeutic efficacy and the provision of such information would transform the field of MSC therapy for the treatment of GvHD.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine emergency medicine graft versus host disease
- medical and health sciences clinical medicine transplantation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-CIG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MC-CIG - Support for training and career development of researcher (CIG)
Coordinator
W23 Maynooth
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.